The Ambulatory Medical Assistance (AMA) programme during active‐phase treatment in patients with haematological malignancies: A cost‐effectiveness analysis-Reference-Cited by-同舟云学术

The Ambulatory Medical Assistance (AMA) programme during active‐phase treatment in patients with haematological malignancies: A cost‐effectiveness analysis

Published:2022-09-27 Issue:6 Volume:31 Page:
ISSN:0961-5423
Container-title:European Journal of Cancer Care
language:en
Short-container-title:European J Cancer Care

Author:

Michallet Anne‐Sophie¹,Malartre Stephanie¹,Vignaud Elodie¹,Bocquet Alexiane¹,Sontag Pascale¹,Galvez Christelle¹,Blay Jean‐Yves¹,Heudel Pierre¹,Vimont Alexandre²^ORCID,Blachier Martin²,Ferrua Marie³,Minvielle Etienne³⁴,Mir Olivier⁵

Affiliation:

1. Leon Berard Cancer Center Lyon France

2. Public Health Expertise Paris France

3. Division of Interdisciplinary Patient Care Pathways (DIOPP) Gustave Roussy Villejuif France

4. I3‐CRG, Ecole polytechnique‐CNRS Palaiseau France

5. Department of Ambulatory Cancer Care Gustave Roussy Villejuif France

Publisher

Hindawi Limited

Subject

Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ecc.13709

Reference21 articles.

1. ATIH. (2020).National micro‐costing study 2020. Available from:https://www.atih.sante.fr/information-sur-les-couts/etudes-nationales-de-couts-presentation-et-recrutement

2. The efficacy and cost‐effectiveness of patient navigation programs across the cancer continuum: A systematic review

3. Cancer care coordinators in stage III colon cancer: a cost-utility analysis

4. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

5. Ambulatory Medical Assistance - After Cancer (AMA-AC): A model for an early trajectory survivorship survey of lymphoma patients treated with anthracycline-based chemotherapy

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Retrospective, real‐life study of venetoclax plus azacitidine or low‐dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy;Cancer Medicine;2022-12-08